RxDoctor Payments Data

Jacqueline Ng, MD

Ophthalmology · Lake Oswego, ORNPI 1033435961

Payments from drug & device makers

$1,235in general payments, 2019–2025

Across 27 payments — averaging $45.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$535
  • Rxsight Inc$370
  • Johnson & Johnson Surgical Vision, Inc.$131
  • Lombart Brothers, Inc.$45
  • Kala Pharmaceuticals, Inc.$36
  • Aerie Pharmaceuticals, Inc.$25
  • plus $93 from 5 others

What the payments were for

  • Food & beverage$1,21698%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,235 in reported general payments places this provider in the 65th percentile of 248 ophthalmology providers in Oregon.

See all ophthalmology providers in Oregon

Medicare billing

Part B allowed, 2024
$275,201
Medicare patients
843
Services billed
2,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine119$137,812
Cyclosporine46$26,917
TyrvayaVarenicline Tartrate21$17,186
Prednisolone Acetate235$7,880
VyzultaLatanoprostene Bunod17$6,377
Latanoprost364$5,120
Ketorolac Tromethamine153$3,831
Ofloxacin206$2,749
Loteprednol Etabonate16$2,222
Fluorometholone35$2,200
Brimonidine Tartrate123$1,842
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat100$1,771
Timolol Maleate117$1,655
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha92$1,227
Azelastine Hcl57$1,154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Oyster Point Pharma, Inc.Tyrvaya$18$17,18621 claims
Bausch & Lomb Americas Inc.Vyzulta$15$6,37717 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$19$2,22216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 248 ophthalmology providers in Oregon.

Other ophthalmology in Lake Oswego

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →